FPW
REGN icon

Fairvoy Private Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Fairvoy Private Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,092
Closed -$844K – 223
2026
Q1 		$844K Buy
+1,092
New +$836K 0.2% 102

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Fairvoy Private Wealth's REGN Position: Q2 2026 in Review

Fairvoy Private Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 1,092 shares — an estimated $844K sold.

Fairvoy Private Wealth first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $844K in Q1 2026. 237 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Fairvoy Private Wealth reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fairvoy Private Wealth sold 1,092 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $844K.
  • Fairvoy Private Wealth first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Fairvoy Private Wealth's Regeneron Pharmaceuticals position peaked at $844K in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Fairvoy Private Wealth's 13F filing for Q2 2026, filed 17 Jul 2026.